| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5360 | 2012 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3489 | 2014 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1450 | 2016 |
| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1325 | 2019 |
| ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer AJ Armstrong, RZ Szmulewitz, DP Petrylak, J Holzbeierlein, A Villers, ... Journal of Clinical Oncology 37 (32), 2974-2986, 2019 | 1035 | 2019 |
| Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ... Molecular cancer research 9 (8), 997-1007, 2011 | 779 | 2011 |
| Prostate cancer, version 1.2016 JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ... Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016 | 776 | 2016 |
| Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity B Shuch, A Amin, AJ Armstrong, JN Eble, V Ficarra, A Lopez-Beltran, ... European urology 67 (1), 85-97, 2015 | 560 | 2015 |
| Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 488 | 2017 |
| Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ... Journal of clinical oncology 34 (14), 1652-1659, 2016 | 454 | 2016 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 448 | 2016 |
| A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis AJ Armstrong, ES Garrett-Mayer, YCO Yang, R De Wit, IF Tannock, ... Clinical Cancer Research 13 (21), 6396-6403, 2007 | 434 | 2007 |
| Prostate cancer, version 2.2014 JL Mohler, PW Kantoff, AJ Armstrong, RR Bahnson, M Cohen, ... Journal of the National Comprehensive Cancer Network 12 (5), 686-718, 2014 | 399 | 2014 |
| Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide KL Noonan, S North, RL Bitting, AJ Armstrong, SL Ellard, KN Chi Annals of oncology 24 (7), 1802-1807, 2013 | 391 | 2013 |
| Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer RL Bitting, AJ Armstrong Endocrine-related cancer 20 (3), R83-R99, 2013 | 389 | 2013 |
| NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 375 | 2021 |
| Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ... Journal of Clinical Oncology 34 (18), 2098-2106, 2016 | 374 | 2016 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019 | 333 | 2019 |
| Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer AJ Armstrong, E Garrett-Mayer, YC Ou Yang, MA Carducci, I Tannock, ... Journal of Clinical Oncology 25 (25), 3965-3970, 2007 | 315 | 2007 |
| Prostate cancer, version 3.2012 featured updates to the NCCN guidelines JL Mohler, AJ Armstrong, RR Bahnson, B Boston, JE Busby, AV D’Amico, ... Journal of the National Comprehensive Cancer Network 10 (9), 1081-1087, 2012 | 289 | 2012 |
